What happened this week in GLP‑1s?
Every significant GLP-1 development since 2017, dated and sourced: 1,965 events across approvals, trials, prices, lawsuits, compounding and culture.
Latest
- Safety
Rule 702 general causation hearing opens in MDL 3094
Judge Marston opened a multi-day hearing on whether plaintiffs' general causation experts may testify, alongside defense motions for summary judgment on multiple injury categories. The Eastern District of Pennsylvania's MDL 3094 page states the hearing runs from September 14, 2026 through September 18, 2026. It is the pivotal event in the litigation to date: without admissible general causation evidence, claims cannot reach a jury. As of September 14, 2026 no ruling had issued.
- Prices
Status check: the two Medicare prices for semaglutide in 2027 still have not been reconciled
Two different government prices for semaglutide are scheduled to apply in 2027 and CMS has not publicly resolved which governs. The Inflation Reduction Act negotiation set a maximum fair price of about $274 for the Ozempic, Rybelsus and Wegovy group effective January 1, 2027, with $276.78 on commonly used Ozempic and Rybelsus presentations and $385.63 on the highest Wegovy dose. The separate most-favored-nation agreement set $245 for Medicare and Medicaid. Analysts have said publicly it is unclear which price is the real one.
- Safety
Still no NAION warning on any US tirzepatide label
As of this refresh, full-text search of the current Mounjaro and Zepbound prescribing information returns no occurrence of 'NAION' or 'optic neuropathy', 21 months after the FDA first listed NAION as a class potential signal naming both products, and 15 months after European regulators added it to semaglutide labeling. No FDA statement explaining the divergence was located.
- Safety
Australian regulator finds eight times the approved semaglutide dose in a product sold as retatrutide
Australia's Therapeutic Goods Administration published a safety alert on September 14 after laboratory testing of a product sold as retatrutide, obtained in its original unmarked vial, found no retatrutide at all but undeclared semaglutide at roughly eight times the level in approved semaglutide products. The consumer who used it vomited uncontrollably, tore an esophagus and required hospital treatment. The TGA said retatrutide is unapproved by any comparable regulator, that any retatrutide obtained outside a clinical trial may be counterfeit, and that it has not located the source; penalties reach A$1.82 million per breach for individuals and seven years imprisonment.
- Safety
Court weighs expert evidence in the GLP-1 stomach injury MDL
A hearing on the admissibility of plaintiffs' expert evidence under Rule 702 in MDL 3094 was scheduled for mid-September 2026, the litigation's biggest test so far. Litigation trackers give the window variously as September 10 to 18 and September 14 to 18; the exact start date is unconfirmed against the court docket. The rulings will decide what scientific testimony reaches bellwether juries.
- Research
EASD 2026 in Milan sets up the next round of competitor data
The 62nd annual meeting of the European Association for the Study of Diabetes runs September 28 to October 2 at the Milan Convention Centre, with a scientific program from September 29. Expected obesity and incretin presentations include Eli Lilly's eloralintide plus tirzepatide Phase 2 data on September 30, SYNCHRONIZE-2 results for Boehringer Ingelheim's survodutide in obesity with type 2 diabetes, AstraZeneca's AZD6234 amylin data, and additional Hengrui ribupatide results. Roche's Pharma Day on September 28 falls in the same window.
- Business
Generic liraglutide cash prices run three to eleven times below the weekly brands, depending on the dose
GoodRx cash prices captured on 2026-09-14 show generic liraglutide at $112.19 with a coupon for a two-pen diabetes carton (retail $615.85) and $372.45 for a five-pen weight-management carton (retail $717.63), against listings above $1,200 for Ozempic and Mounjaro on the same site. That is roughly an eleven-fold gap at the 1.8 mg diabetes dose but only about a three-fold gap at the 3 mg weight-management dose, where generic competition is thinner. Nine companies list a Victoza-referenced product and four a Saxenda-referenced product in the FDA drug code directory; those thirteen labels sit on eight generic applications plus one authorized generic.
- Research
Label check: what the current Zepbound prescribing information actually says about dosing
The Zepbound US prescribing information, revised 08/2026 and read in full on this date, lists four presentations: single-dose pen, single-dose vial, multi-dose vial and single-patient-use KwikPen, with the multi-dose vial and KwikPen each holding four doses of one strength. The recommended starting dosage is 2.5 mg weekly for 4 weeks; recommended maintenance dosages are 5, 10 or 15 mg for weight reduction and 10 or 15 mg for obstructive sleep apnea, with a 15 mg maximum. Recent Major Changes include a never-share KwikPen warning (01/2026), a severe gastrointestinal adverse reactions update (02/2026), removal of the suicidal behavior and ideation warning (02/2026), and a diabetic retinopathy complications update (08/2026). SURMOUNT-MAINTAIN is not yet reflected in the label, which still cites the SURMOUNT-4 randomized withdrawal trial.
- Business
Novo Nordisk rebrands as 'Novo' and introduces 'The Novo Way'
One week before its Capital Markets Day, the company adopted the single name 'Novo' for day-to-day use with the tagline 'Lasting Health Starts Now', keeping Novo Nordisk A/S as its legal name and the Apis bull logo in updated form. It also launched a cultural framework built on customer obsession, competitiveness, clarity, and care and integrity. Product brand names were unchanged.
- Competition
Roche heads into Pharma Day with three obesity mechanisms in hand
Roche's September 28 Pharma Day is expected to cover Phase 2 results for enicepatide in obesity with type 2 diabetes, whose companion study carries a September 24 completion date, plus updates on the once-daily oral CT-996, the antibody emugrobart in combination with tirzepatide, and petrelintide with partner Zealand Pharma. Roche has said it wants to be a top-three obesity player and has pointed to enicepatide, which produced 22.5 percent placebo-adjusted weight loss at 48 weeks in Phase 2, as a potential best-in-class asset. The August Hanmi license added a third non-incretin mechanism alongside amylin.
- Prices
Semaglutide cash prices settle into a $149 to $499 band while list prices stay above $1,000
As of mid-September 2026 the cheapest branded route is the Wegovy or Ozempic pill at $149 a month, the pens run $199 introductory and $349 standard, Wegovy HD is $399 and Ozempic 2 mg is $499, all against list prices of $1,027.51 for Ozempic and $1,349.02 for Wegovy.
- Competition
Sixteen challenger programs are now in Phase 3, and none reads out before 2027
Recruiting Phase 3 obesity programs in the United States as of September 2026 include aleniglipron with ACCOMPLISH-1 and -2, eloralintide across five ENLIGHTEN trials, enicepatide in three trials, elecoglipron in nine, AZD6234 in three SELENE trials, ribupatide in three KaiNETIC trials, berobenatide, ASC30 with AURORA-1 and -2, and several MariTide outcomes and extension studies. Earliest primary completions cluster in 2028, with MariTide's January 2027 dates the nearest exception. The practical consequence is that the branded market stays a two-company market through 2027 whatever the pipeline looks like on paper.
- Policy
Status check: BALANCE state window closes January 1 with one committed state and no CMS participant count
With 109 days left in the state Medicaid application window that closes January 1, 2027, CMS has still not published a participant count for the BALANCE model, and only Indiana has been publicly identified as committing. CMS delayed the Medicare Part D half of BALANCE indefinitely in April after insufficient plan interest and extended the Bridge through December 2027 instead. Nothing has been announced about what covers Medicare obesity prescriptions in 2028.
- Prices
Status check: Bridge copays are excluded from every Part D affordability mechanism
Because the Medicare GLP-1 Bridge operates outside the Part D benefit, the $50 monthly copay does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap in 2026, cannot be reduced by Extra Help, and cannot be spread across the year through the Medicare Prescription Payment Plan. Twelve months of Bridge copays comes to $600 in spending that does nothing to move a beneficiary toward catastrophic coverage on their other medications.
- Policy
Status check: no state has been named as a BALANCE participant and Medicare coverage after 2027 remains undecided
Two coverage questions that shape 2028 for US GLP-1 patients are open as of mid-September. CMS has not named a single participating state under BALANCE, the model intended to replace the Bridge in Medicaid, and has announced no successor arrangement for Medicare obesity coverage when the Bridge expires December 31, 2027. The Treat and Reduce Obesity Act, which would lift the statutory Part D exclusion, has 51 House and 19 Senate cosponsors and has not moved.
- Prices
Status check: Novo Nordisk's $675 list price still lands well above every negotiated and cash price
Novo Nordisk's announced reduction takes the US list price of Wegovy, Ozempic and Rybelsus to $675 a month on January 1, 2027, a cut of roughly 50 percent for Wegovy and 35 percent for Ozempic. That figure sits far above the $245 most-favored-nation price, the roughly $274 Inflation Reduction Act maximum fair price, and NovoCare cash prices of $349 for the pen and $149 to $299 for the pill. The cut matters mainly for patients on coinsurance or inside a deductible, not for cash payers.
- Prices
Status check: the Zepbound formulary class action against CVS Caremark remains live as restoration nears
The class action challenging CVS Caremark's July 2025 removal of Zepbound from its largest commercial templates survived a motion to dismiss in late August and remains active as the October 1 restoration approaches. Caremark's May 28 announcement returns Zepbound as an additional preferred option on formularies covering an estimated 25 million to 30 million people, but employers still decide whether to cover weight-management drugs at all, so formulary placement does not by itself restore any individual's coverage.
- Science
The lean-mass race now spans a dozen programs and one approved drug
Preserving muscle during incretin-driven weight loss has become its own competitive lane, with Eli Lilly's bimagrumab, Scholar Rock's apitegromab, Regeneron's trevogrumab with garetosmab, and Veru's oral enobosarm all in mid-stage testing alongside GLP-1 therapy, and Roche holding two non-incretin bets in petrelintide and the newly licensed HM17321. Published Phase 2 work reported that apitegromab with tirzepatide gave 54.9 percent greater relative lean-mass retention than tirzepatide alone, and that bimagrumab plus semaglutide produced roughly 22 percent weight loss with about 92 percent of it from fat. Scholar Rock's September 11 approval in spinal muscular atrophy is the first regulatory validation of the underlying mechanism, though none of these agents is approved for use with obesity drugs.
- Research
Tirzepatide evidence base: what has reported and what has not
As of this date, tirzepatide has published results across SURPASS 1-6, SURPASS J-mono, J-combo, AP-Combo, PEDS, SWITCH, EARLY, CN-MONO and CVOT; SURMOUNT 1-5, OSA, J, CN and MAINTAIN; SUMMIT; and SYNERGY-NASH. Still unreported: SURMOUNT-MMO (estimated October 2027), SURPASS-T1D-1 and -2 (estimated November 2026), TRIUMPH-5 (estimated November 2026), TREASURE-CKD (completed, unreported) and SURPASS-CN-INS (completed, unpublished).
- Business
Where semaglutide stands in September 2026
As of mid-September 2026 semaglutide is sold as Ozempic injection and tablets, Wegovy injection, Wegovy HD and the Wegovy pill, covering diabetes, heart, kidney, weight and liver indications. Novo Nordisk faces a December CagriSema decision, an expanding generic threat abroad and a US market where Eli Lilly leads on prescriptions.
- Prices
Aetna posts a Standard Control Choice formulary addition for Zepbound effective October 1
Aetna's formulary update documents list Zepbound as an addition to the Standard Control Formulary Choice in the Endocrine and Metabolic, Antiobesity class effective October 1, 2026, the operational reflection of the Caremark decision inside a CVS Health-owned carrier. The listing is the first plan-level confirmation that the restoration is being implemented rather than merely announced, though exclusions, precertification, quantity limits and step therapy still apply and remain subject to change.
- Research
Amgen's MariTide readouts now sit outside the 2026 window
MariTide, a peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor, is in nine global Phase 3 studies across obesity, obstructive sleep apnea, cardiovascular disease and heart failure, with the primary readout for MARITIME-1 guided to early 2027 and MARITIME-1 and MARITIME-2 carrying primary completion dates of January 21, 2027. Phase 2 reported roughly 20 percent average weight loss at 52 weeks on the efficacy estimand without a plateau, and 12.3 to 16.2 percent on the treatment-policy estimand, alongside high discontinuation and vomiting rates that led Amgen to slow Phase 3 dose escalation. A Phase 3 switch study is enrolling patients moving off weekly tirzepatide or semaglutide.
- Research
AstraZeneca's obesity case rests on two readouts due this fall
AstraZeneca started three Phase 3 SELENE trials of the amylin analog AZD6234 in August 2026 with primary completion in August 2028, one of them testing the drug as an add-on for people already on an incretin, and moved the oral GLP-1 elecoglipron into Phase 3 in obesity and type 2 diabetes with readouts analysts place in 2027 or 2028. Nearer term, the company is expected to present AZD6234 data at EASD, plus Phase 2 results in participants on stable background GLP-1 therapy and from the Phase 2b ASCEND study of the GLP-1/glucagon dual agonist AZD9550 combined with AZD6234. Detailed Phase 2 numbers for AZD6234 have not been published.
- Search trends
Baseline keyword and SERP landscape captured for semaglutides.org
A dedicated tirzepatide pass harvested 13,213 clean US queries from Google and DuckDuckGo autocomplete across 86 seeds, clustered them into 38 topic clusters, probed 75 competitor URLs for live status, and sampled r/Zepbound, r/Mounjaro and r/compoundedtirzepatide. The first pass had tracked 67 Mounjaro and 88 Zepbound queries; this pass raises tirzepatide coverage to 1,213 tracked queries and adds root-level Mounjaro, Zepbound and tirzepatide hubs to the site architecture.
- Compounding
Branded tirzepatide self-pay prices sit far below the shortage-era gap
A price index covering 14 telehealth providers recorded a median first-month price of $197 for compounded semaglutide and $299 for compounded tirzepatide as of September 3, 2026, against $199 to $349 for the Wegovy pen and $299 to $449 for Zepbound before membership fees. Noom's brand-medication track was listed at $39 for the first month then $129 a month, and WW Med+ at $25 a month for an introductory period, as read from company sites on September 5. The persistence of the gap is why the compounded market survives enforcement that has removed its main legal footing.
- FDA & regulation
China's semaglutide generics remain stuck behind data exclusivity
Semaglutide's Chinese patent has lapsed, but generic approvals from Hangzhou Jiuyuan Gene Engineering, Livzon Pharmaceutical Group and The United Laboratories remain suspended rather than rejected while regulators work through a data exclusivity period tied to the China-Switzerland free trade agreement. Jiuyuan's Jikeqin, a generic referencing Wegovy, was accepted for review in February 2026; Huadong Medicine and CSPC have filings of their own. Eleven or more Chinese programs are in late-stage development, so the queue behind the exclusivity question is long.
- Business
Chinese licensing keeps setting the price of entry into obesity
Deal trackers covering 2026 put AstraZeneca's obesity and diabetes collaboration with CSPC at the top of the year's licensing table at up to $18.5 billion with $1.2 billion up front, ahead of Bristol Myers Squibb with Hengrui at up to $15.2 billion and Pfizer with Innovent at up to $10.5 billion. Menarini's September deal for Gan & Lee's bofanglutide and Genentech's August license for Hanmi's HM17321 extend the pattern into Europe and Korea. More than 100 China-origin licensing deals have been signed since the start of 2025, with the quarterly peak in the first three months of 2026.
- Policy
CMS has not yet published the 2027 Medicare Advantage and Part D landscape a month before open enrollment
CMS finalized 2027 Medicare Advantage and Part D rules and payment policies but said the finalized plan landscape, average premiums and county-level plan details would be released in mid-to-late September, ahead of the annual enrollment period running October 15 to December 7. Because the Medicare GLP-1 Bridge operates outside Part D, plan choice does not determine Bridge eligibility, but it does determine cost sharing for anyone routed back to Part D by a diabetes, sleep apnea or MASH diagnosis.
- Research
Corbus reports 5 percent weight loss for its peripheral CB1 pill in Phase 1b
Corbus Pharmaceuticals announced positive topline data from CANYON-1, a Phase 1b study of the once-daily oral CB1 inverse agonist CRB-913 in obesity, reporting statistically significant mean weight loss of 5.0 percent at the 60 mg dose after 12 weeks against 0.0 percent on placebo, with 44.4 percent of participants losing at least 5 percent and no plateau observed. The company plans a Phase 2 obesity study in 2027 and will present full data in a late-breaking session at ObesityWeek in November. CRB-913 is designed to be far less brain-penetrant than earlier CB1 drugs, the class withdrawn for neuropsychiatric harm.
- Prices
India's generic semaglutide market settles into a price war six months on
Six months after India's semaglutide patent lapsed on March 20, 2026, more than 40 approved generic brands are in circulation and pricing has compressed sharply: Dr. Reddy's launched Obeda at about 4,200 rupees a month while rivals including Sun Pharmaceutical, Lupin, Natco and Mankind launched on the same day at prices reported as low as 325 to 750 rupees per weekly injection. Novo Nordisk has cut its own Indian prices in response, from a starting point of roughly 8,800 to 10,000 rupees a month. Dr. Reddy's has said it is targeting 87 countries in 2026, with Canada and Brazil already approving generics.
- FDA & regulation
Mazdutide's US path stays theoretical as Lilly publishes a Phase 2
Mazdutide remains approved only in China, for chronic weight management since June 2025 and for type 2 diabetes glycemic control since September 2025, and is not approved or under review by the FDA. Eli Lilly, which originated the molecule and holds rights outside China, published a 179-participant US Phase 2 in The Lancet Diabetes and Endocrinology on August 21, 2026 but has announced no Phase 3 program or FDA filing. Lilly's stated US obesity priorities remain tirzepatide, orforglipron and retatrutide.
- Competition
Pfizer's obesity case now rests on a single monthly injectable
After cutting MET-224o and PF-07976016 in August, Pfizer's obesity portfolio centers on berobenatide, the ultra-long-acting GLP-1 formerly known as MET-097i, with three Phase 3 trials already running, VESPER-4, VESPER-5 and VESPER-6, and a plan to advance ten Phase 3 studies during 2026 including a switch trial from approved weekly therapies to monthly dosing. Phase 2b data showed placebo-corrected weight loss of up to 12.3 percent at 28 weeks on the medium Phase 3 monthly dose, and about 16 percent mean loss over 32 weeks at the high weekly dose. Leerink has said the asset's value hinges on Phase 3 results in 2028.
- FDA & regulation
Status check: GLOBE and GUARD drug-pricing model rules remain unfinalized nine months after proposal
CMS proposed two Innovation Center payment models on December 23, 2025 that would change how inflation rebates are calculated using international price benchmarks: GLOBE for certain Part B drugs and GUARD for certain Part D drugs. Comments closed February 23, 2026 and neither rule has been finalized. The American Hospital Association warned that manufacturers would likely adjust list prices to reduce GLOBE rebates, with knock-on effects for Average Manufacturer Price and therefore Medicaid rebate math on drugs including GLP-1s.
- Policy
Status check: Marketplace plans remain the weakest GLP-1 coverage channel heading into 2027
Obesity medications are not an essential health benefit under the Affordable Care Act, so Marketplace carriers are not required to cover them. A Leverage|Axiaci review of all 300 carriers offering 2026 individual and family plans found only 26 covering GLP-1s for obesity, concentrated in nine states, with all but four restricting coverage to a BMI of 40 or above. Enrollment with any such coverage fell from 3.6 million in 2024 to 2.8 million in 2026, and 2027 benchmark premiums are rising again.
- Policy
Status check: PBM delinking under the 2026 appropriations law does not bite until 2028
The Consolidated Appropriations Act, 2026 introduced delinking in Medicare Part D, limiting pharmacy benefit manager compensation to bona fide service fees unconnected to drug price or rebate volume, and required standardized transparency and full rebate pass-through for ERISA plans. Most provisions do not take effect until August 2028, with some in January 2029. For GLP-1 formulary decisions through 2027, the rebate-driven economics that produced the Caremark exclusion and its reversal remain in place.
- Research
Survodutide heads to EASD without a filing date
Boehringer Ingelheim has not published a US filing date or expected launch for survodutide despite reporting up to 16.6 percent average weight loss at 76 weeks in the pivotal SYNCHRONIZE-1 trial in April 2026, with about 85 percent of participants losing at least 5 percent. SYNCHRONIZE-2 results in participants with type 2 diabetes are expected at EASD at the end of September. The GLP-1/glucagon dual agonist holds FDA breakthrough therapy designation in MASH, with two Phase 3 liver trials under way and a cardiovascular outcomes trial running.
- Compounding
The compounding fight has moved from courtrooms to dockets and ad panels
As of mid-September 2026 the litigation track that defined 2025 has largely resolved against compounders: the Fifth Circuit upheld both shortage delistings, a federal judge dismissed the Strive antitrust suit with prejudice, and Lilly's cases against telehealth platforms survive in narrowed form. What remains open sits in administrative and self-regulatory channels: the unfinalized 503B bulks exclusion, Novo's demonstrable-difficulties nomination, the 503A peptide bulks rulemaking, and ten National Advertising Division cases. The Seventh Circuit argument on retatrutide's classification on September 24 is the next scheduled decision point.
- Research
Viking's VK2735 maintenance data remains the quarter's outstanding small-cap readout
Viking Therapeutics has guided data from a Phase 1 maintenance-dosing study of subcutaneous VK2735 to the third quarter of 2026, testing whether patients can hold weight loss on monthly injections or oral regimens after weekly induction, and the company has said patients retained most of their loss four weeks after the final dose. Phase 3 VANQUISH-1 and VANQUISH-2 are fully enrolled, and a Phase 3 of the oral formulation is guided to start in the fourth quarter. Viking closed the second quarter with $502 million in cash after a July follow-on raise of about $159.6 million.
- Culture
AI analysis of 400,000 Reddit posts surfaces side effects that rarely reach trials
Coverage of a Penn AI study analyzing roughly 400,000 GLP-1 Reddit posts highlighted symptom clusters users discuss heavily but that appear little in trial adverse event tables, including taste changes, altered alcohol response and sleep effects. Social-media mining cannot establish incidence or causation and skews toward people with problems or enthusiasm. It is being used as a hypothesis generator for formal pharmacovigilance.